AstraZeneca is partnering with Oracle to use AI and real-world data to accelerate clinical trial recruitment. The collaboration will apply an AI model across multiple therapeutic areas and includes an initial program with Abu Dhabi-based M42 focused on identifying patients with uncontrolled hypertension for planned studies. The stated goal is to find and match participants sooner, improve safety monitoring workflows, and generate evidence continuously over the product lifecycle. AstraZeneca and Oracle plan to develop reusable technical components and define common outcome measures to evaluate where the approach can scale across geographies. For biotech operations teams, this is a concrete attempt to reduce one of the persistent execution bottlenecks in clinical development—trial start delays driven by slow or fragmented patient identification.